Ironshore Pharmaceuticals & Development, Inc., today announced that the U.S.Food and Drug Administration has accepted the resubmission of the New Drug Application for HLD200, Ironshore’s lead compound currently under review as a new treatment for Attention Deficit Hyperactivity Disorder and set a Prescription Drug User Fee Act date of August 8, 2018.
July 12, 2018
· 2 min read